Glenmark Plans To Spin Out A US-Based ‘Innovation’ Business – And May Pull The Plug On Advair

Having amassed a significant pipeline of innovative assets, India’s Glenmark has made the choice to spin them off into a new company that will be housed in the US. 

Basketball
Spinning off its innovative assets will bring a “strong, heightened focus," Glenmark believes. • Source: Shutterstock

Glenmark Pharmaceuticals’ specialty assets, including its proposed biosimilar to Xolair (omalizumab), will continue to be housed inside Glenmark and will not form part of a spun-out ‘innovation’ business that the Indian firm has announced plans to establish in the US.

As would be expected, Glenmark’s generic assets will also remain with the residual Glenmark business, the company confirmed. The transfer...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Strategy

More from Business